Biotechnology

Outlook Therapeutics

Outlook Therapeutics released FY2026 Q1 earnings on February 17 (EST), actual revenue USD -1.208 M (forecast USD 3.138 M), actual EPS USD -0.3829 (forecast USD -0.2033)

Outlook Therapeutics released FY2025 Q4 earnings on December 19 (EST), actual revenue USD -92.32K (forecast USD 5.846M), actual EPS USD -0.2816 (forecast USD -0.2775)

Outlook Therapeutics released FY2025 Annual Earnings on December 19 (EST), actual revenue USD 1.414 M (forecast USD 6.719 M), actual EPS USD -1.794 (forecast USD -1.6425)

Douglas Tsao Maintains Hold Rating on Outlook Therapeutics

Outlook Therapeutics Completes Type A Meeting with FDA

Outlook Therapeutics released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 1.505 M (forecast USD 1.663 M), actual EPS USD -0.5499 (forecast USD -0.3525)

Outlook Therapeutics released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 1.505 M and EPS of USD -1.3343

Outlook Therapeutics Appoints Bob Jahr as CEO

Outlook Therapeutics Launches First Bevacizumab Ophthalmic Formulation in Germany and the UK

Outlook Therapeutics Plans Public Offering of Common Stock and Warrants

Outlook Therapeutics released FY2025 Semi-Annual Earnings on May 15 EST, with actual revenue USD 0 and actual EPS USD -1.0531

Outlook Therapeutics released FY2025 Q2 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 702.6 K), actual EPS USD -1.5014 (forecast USD -0.542)

Outlook Therapeutics Plans to Launch LYTENAVA™ for Wet AMD Treatment

Outlook Therapeutics Inc forecasts Q1 2025 EPS loss of 60 cents

Outlook Therapeutics, Inc. announces FDA acceptance of BLA for ONS-5010, review expected by August 27, 2025

HC Wainwright Lowers Outlook Therapeutics' EPS Estimate for Q2 2025 to ($0.60)

Outlook Therapeutics released FY2025 Q1 earnings on February 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS 0.717 USD (forecast -0.6166 USD)

Analysts Set Target Price of $27.40 for Outlook Therapeutics with Moderate Buy Consensus Rating from Six Brokerages

Outlook Therapeutics released FY2024 earnings on December 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.0631 USD (forecast -5.4075 USD)

Outlook Therapeutics released FY2024 Q4 earnings on December 27 (EST), with actual revenue of 0 USD and actual EPS of 0.2398 USD (forecast EPS was -0.802 USD)

Visionary

Sky Quarry

TMD Energy

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Semilux

Cocrystal Pharma

Sidus Space

Swarmer

Franklin Covey

Biodexa Pharmaceuticals

Kiniksa Pharmaceuticals

MiMedx

Rigel Pharma

CapForce Inc.

OpGen

Vertex Pharma

Argenx

Alnylam Pharma

Beigene

Natera

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Outlook Therapeutics(OTLK.US)

Outlook Therapeutics Stock Performance Chart